Teriparatide

Product Name: Teriparatide

Form: Free base

CAS No: 52232-67-4

Molar Mass: 4117.72

Chemical Formula: C181H291N55O51S2

Synonyms: LY 333334, Osteotide, Movymia

Storage: Store at -20℃

Sequence: SVSEIQLMHN LGKHLNSMER VEWLRKKLQD VHNF

Target: PTH1 RA

Application:

Teriparatide (CAS: 52232-67-4) stands as a pivotal pharmaceutical agent in the realm of osteoporosis management. As a recombinant form of parathyroid hormone (PTH), teriparatide plays a crucial role in bone metabolism and calcium homeostasis. Its mechanism involves intermittent administration, stimulating osteoblast activity and enhancing bone formation. By promoting bone mineral density and bone strength, teriparatide is instrumental in reducing the risk of fractures in individuals with severe osteoporosis. This targeted approach to bone health makes teriparatide a valuable therapeutic option, especially for those who have not responded well to other treatments. In the field of pharmaceuticals, teriparatide exemplifies a strategic intervention to address the challenges of osteoporosis and promote skeletal health effectively.

Current Research:

Teriparatide is a recombinant form of parathyroid hormone (PTH) used primarily in the treatment of osteoporosis. It is indicated for individuals at high risk of fracture, including postmenopausal women and men with osteoporosis, as well as those with glucocorticoid-induced osteoporosis. Unlike traditional treatments that primarily aim to inhibit bone resorption, teriparatide stimulates new bone formation by promoting the activity of osteoblasts, the cells responsible for bone formation. This anabolic (bone-building) effect makes teriparatide an effective therapy for patients with severe bone loss and those who have not responded to other osteoporosis treatments.

Mechanism of Action
Teriparatide works by mimicking the effects of natural parathyroid hormone (PTH), a key regulator of calcium and bone metabolism. When administered intermittently, teriparatide stimulates osteoblast activity, leading to new bone formation. It enhances the deposition of minerals into the bone matrix, thereby increasing bone density and strength. Teriparatide also helps to improve the balance between bone formation and resorption, by decreasing the activity of osteoclasts (bone-resorbing cells). This anabolic effect is crucial in reversing the bone loss seen in osteoporosis and in reducing the risk of fractures.

Indications and Uses
Teriparatide is primarily used for the treatment of osteoporosis in patients at high risk of fractures. It is prescribed for postmenopausal women with osteoporosis who are at high risk for fracture, men with osteoporosis, and patients who have osteoporosis due to prolonged glucocorticoid use. Teriparatide is typically administered as a daily subcutaneous injection, and treatment is generally limited to a 24-month duration due to concerns about potential risks with long-term use. After a course of teriparatide, patients are usually transitioned to antiresorptive therapies such as bisphosphonates or denosumab to maintain the gains in bone density.

Efficacy and Clinical Benefits
Clinical studies have demonstrated that teriparatide significantly increases bone mineral density (BMD) and reduces the risk of fractures, including both vertebral and non-vertebral fractures. It is one of the few treatments that stimulate bone formation, making it particularly effective for individuals with severe osteoporosis or those who have failed other treatments. The effects of teriparatide on BMD and fracture risk are rapid, with significant improvements often observed within the first few months of treatment. Additionally, teriparatide has been shown to improve bone strength and reduce the incidence of fractures, particularly in patients who have experienced previous fractures.

Safety and Tolerability
Teriparatide is generally well tolerated, with the most common side effects being mild and transient. These may include injection site reactions, nausea, dizziness, and leg cramps. A more serious but rare side effect is osteosarcoma, a type of bone cancer, which has been observed in animal studies. As a result, teriparatide is contraindicated in individuals with a history of bone metastases, skeletal malignancies, or other predisposing factors for bone cancer. Other concerns include hypercalcemia (elevated calcium levels in the blood) and potential renal issues, so monitoring of calcium levels and renal function is recommended during therapy. Teriparatide should be used cautiously in patients with a history of kidney stones or other conditions affecting calcium metabolism.

Advantages and Limitations
Teriparatide’s primary advantage over other osteoporosis treatments is its ability to stimulate new bone formation, rather than merely inhibiting bone resorption. This makes it a particularly effective option for patients with severe bone loss or those at high risk for fractures. However, its use is limited to 24 months due to the potential risk of osteosarcoma and the need for careful monitoring. After the initial therapy with teriparatide, patients typically transition to other osteoporosis medications to maintain bone density and further reduce fracture risk.

Future Directions
Research is ongoing to better understand the long-term benefits and risks of teriparatide, as well as its potential use in combination with other treatments for osteoporosis. There is also interest in exploring the use of teriparatide in other bone-related conditions, such as bone healing after fractures, in patients with low bone mass or those with certain metabolic bone diseases. Additionally, newer formulations and delivery methods for teriparatide are being investigated to improve patient convenience and adherence to treatment.

Reference:

Krege, J. H., Gilsenan, A. W., Komacko, J. L., & Kellier Steele, N. (2022). Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. Journal of Bone and Mineral Research Plus, 6(9), e10665.